Psychedelics such as psilocybin and MDMA may be a promising treatment avenue for Prolonged Grief Disorder (PGD).

Randomized clinical trials demonstrated the efficacy of psilocybin in reducing symptom severity in depression and MDMA in reducing PTSD symptomatology.

Furthermore, psychedelics often produce subjective effects (such as transcendence, mystical experiences, and a sense of oneness) that may be uniquely relevant to the existential distress experienced in PGD.